CAMBRIDGE, Mass. and BEIJING, China, August 21, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd.(NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and…Original Article
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
